DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3030% below fair value

$83.33+1.94 (+2.38%)

Close on Nov 13, 2026Market cap $31.08BP/E 32.8Yield –

DexCom EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

DexCom's EV/EBITDA was 20.8× on Nov 11, 2026, against 22.4× a year earlier. Over the last 5 years it ranged from 18.9× to 128.4×, with a median of 50.3×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	20.8×	−2.7
2025	Dec 31, 2025	23.5×	−9.9
2024	Dec 31, 2024	33.4×	−32.7
2023	Dec 29, 2023	66.1×	−32.8
2022	Dec 30, 2022	98.9×	−8.8
2021	Dec 31, 2021	107.7×	+10.5
2020	Dec 31, 2020	97.3×	−693.1
2019	Jan 31, 2019	790.3×	+125.7
2018	Dec 31, 2018	664.6×	–

Where these numbers come from

Parsed from the XBRL in DexCom's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-1 split on Jun 13, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DXCM.

Compare: DXCM vs MMED · DXCM vs PODD · DXCM vs TNDM · DXCM vs RMD · DXCM vs TFX

Revenue growth13.0% · median 14.3%

Gross margin63.4% · median 58.3%

Operating margin24.0% · median 9.4%

Net margin19.4% · median 13.4%

Company	Revenue	Growth
RMD	$5.73B	+9.0%
DXCM	$5.10B	+13.0%
PODD	$3.19B	+26.5%
MMED	$3.10B	+14.3%
TFX	$2.26B	+20.9%
TNDM	$1.08B	+6.8%

Company

Next earnings (est.): Feb 11, 2027, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 11,100
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1093557

Advertisement
300 × 250

See a number that looks wrong?